{"filing":{"accession_number":"0001731122-26-000982","cik":"0001553788","ticker":"SBEVW","company_name":"SPLASH BEVERAGE GROUP, INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-28","primary_document":"e7811_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000982/e7811_8-k.htm"},"events":[{"id":21713,"run_id":19587,"accession_number":"0001731122-26-000982","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Splash Beverage entered into an addendum on July 28, 2026 that materially expands its exclusive global license agreement for CannEpil® to include veterinary therapeutic applications, creating a second FDA-regulated pharmaceutical development program. This expansion significantly broadens the Company's intellectual property rights and commercial opportunity in companion-animal markets valued at $2.6–$3.8 billion (pain management) and $900 million–$1.7 billion (oncology), and the Company is finalizing a joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.","company_name":"SPLASH BEVERAGE GROUP, INC.","ticker":"SBEVW","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21413,"accession_number":"0001731122-26-000982","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Splash Beverage entered into an addendum on July 28, 2026 that materially expands the scope of its exclusive global license agreement for CannEpil® to include veterinary applications—a significant broadening of the licensed field of use. While technically an amendment to an existing license rather than a new acquisition or merger, this represents a material expansion of the Company's intellectual property rights and commercial opportunity, creating a \"second FDA-regulated pharmaceutical development program\" alongside the human program. The press release emphasizes this as a strategic milestone that \"materially broadens the value of the platform\" and positions the Company in substantial companion-animal markets valued at $2.6–$3.8 billion (pain management) and $900 million–$1.7 billion (oncology). This is a material definitive agreement that expands the Company's rights and strategic scope.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:05:15.480286+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21414,"accession_number":"0001731122-26-000982","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Splash Beverage Group announced an expansion of its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second FDA-regulated pharmaceutical development program. This is a material strategic and operational milestone—expanding the field of use for a proprietary pharmaceutical asset into significant companion-animal markets (veterinary oncology and pain management valued at $2.6–$3.8 billion and $900 million–$1.7 billion respectively). The company is also finalizing a joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program. While this is clearly operational and strategic in nature, it does not fit neatly into the specific categories (e.g., it is not an M\u0026A transaction, a material contract alone, or a regulatory milestone in the traditional sense), making `operational_other` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:05:15.480286+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21413,"accession_number":"0001731122-26-000982","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Splash Beverage entered into an addendum on July 28, 2026 that materially expands the scope of its exclusive global license agreement for CannEpil® to include veterinary applications—a significant broadening of the licensed field of use. While technically an amendment to an existing license rather than a new acquisition or merger, this represents a material expansion of the Company's intellectual property rights and commercial opportunity, creating a \"second FDA-regulated pharmaceutical development program\" alongside the human program. The press release emphasizes this as a strategic milestone that \"materially broadens the value of the platform\" and positions the Company in substantial companion-animal markets valued at $2.6–$3.8 billion (pain management) and $900 million–$1.7 billion (oncology). This is a material definitive agreement that expands the Company's rights and strategic scope.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:05:15.480286+00:00","company_name":"SPLASH BEVERAGE GROUP, INC.","ticker":"SBEVW","filing_date":"2026-07-29"},{"id":21414,"accession_number":"0001731122-26-000982","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Splash Beverage Group announced an expansion of its exclusive global license for CannEpil® to include veterinary therapeutic applications, creating a second FDA-regulated pharmaceutical development program. This is a material strategic and operational milestone—expanding the field of use for a proprietary pharmaceutical asset into significant companion-animal markets (veterinary oncology and pain management valued at $2.6–$3.8 billion and $900 million–$1.7 billion respectively). The company is also finalizing a joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program. While this is clearly operational and strategic in nature, it does not fit neatly into the specific categories (e.g., it is not an M\u0026A transaction, a material contract alone, or a regulatory milestone in the traditional sense), making `operational_other` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:05:15.480286+00:00","company_name":"SPLASH BEVERAGE GROUP, INC.","ticker":"SBEVW","filing_date":"2026-07-29"}]}